DANVERS, Mass. – October 28, 2024 – Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Abiomed, Inc. ABMD announced receipt of the FDA’s breakthrough device designation for its Impella ECP expandable percutaneous heart pump. Bestowing of the designation implies that the FDA will ...
Abiomed, part of Johnson & Johnson MedTech, recently presented positive results from the first completed pivotal trial on Impella ECP, a novel transvalvular axial flow pump with compressible pump ...
Results were presented at Transcatheter Cardiovascular Therapeutics, or TCT, 2024 conference from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial ...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two ...
Abiomed, Inc. ABMD announced receipt of the FDA’s breakthrough device designation for its Impella ECP expandable percutaneous heart pump. Bestowing of the designation implies that the FDA will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results